Keith Speights

Keith Speights

TMFFishBiz

Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles






3 Stocks I'm Never Selling

Their competitive advantages and long-term growth prospects make these three stocks keepers.






Is Allergan a Buy?

You might think it's too late to profit with this soon-to-be-acquired drug stock. Think again.